PMID: 6116195Feb 1, 1981

Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs

Naunyn-Schmiedeberg's Archives of Pharmacology
N HimoriT Ishimori


In conscious dogs, the selectivity and duration of beta-blocking activity, and serum concentration of a beta-blocking agent, D-32 [dl-1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol hydrochloride] was compared to that of propranolol, pindolol, atenolol and IPS-339 [dl-1-tert-butylamino-3-(-9-fluorenylideneaminoxy)-2-propanol hydrochloride]. Ratios of doses causing a 50% inhibition of tachycardia to that on hypotension induced by isoprenaline were as follows: D-32 (0.69), propranolol (0.67), atenolol (0.03) and IPS-339 (6.3). Thus, present experiments indicate that, unlike atenolol and IPS-339, D-32, propranolol and pindolol are non-selective beta-adrenoceptor blocking agents. Atenolol and IPS-339, however, selectively blocked cardiac beta1, receptors and vascular beta2-receptors respectively, as would be expected. In an optimal dose range these two drugs can be used satisfactorily as a pharmacological tool for inhibiting responses mediated via the respective beta-receptors. After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pi...Continue Reading


Dec 1, 1975·Clinical Pharmacology and Therapeutics·D G McDevitt, D G Shand
Jul 1, 1977·British Journal of Pharmacology·J L ImbsC G Wermuth
May 1, 1978·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·P R ReevesM J Winrow
May 1, 1977·Clinical Pharmacology and Therapeutics·Y M Traub, J B Rosenfeld
Feb 1, 1978·European Journal of Pharmacology·N HimoriT Ishimori
Apr 24, 1976·British Medical Journal·A P Douglas-Jones, J M Cruickshank
Apr 21, 1973·British Medical Journal·S G CarruthersM J Walsh
Apr 1, 1974·Japanese Journal of Pharmacology·J Yamamoto, A Sekiya
Jan 1, 1974·Naunyn-Schmiedeberg's Archives of Pharmacology·K H RahnG Planz
Jan 1, 1974·European Journal of Clinical Pharmacology·R GuglerH J Dengler

Related Concepts

Xibenolol, (+-)-isomer
IPS 339, monohydrochloride, (+-)-isomer
Adrenergic beta-Antagonists
Canis familiaris
Norepinephrine Receptors

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.